Are you sure this is Waldenstrom macroglobulinemia?

被引:33
作者
Ghobrial, Irene M. [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
关键词
CONSENSUS PANEL RECOMMENDATIONS; 2ND INTERNATIONAL WORKSHOP; LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA; IGM MONOCLONAL GAMMOPATHY; FREE LIGHT-CHAIN; PHASE-II TRIAL; PROGNOSTIC-FACTORS; MULTIPLE-MYELOMA; FOLLOW-UP; RITUXIMAB;
D O I
10.1182/asheducation-2012.1.586
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
Waldenstrom macroglobulinemia (WM) is a rare lymphoproliferative disorder characterized by the presence of lymphoplasmacytic cells in the BM and IgM monoclonal protein in the serum. The origin of the malignant clone is thought to be a B cell arrested after somatic hypermutation in the germinal center and before terminal differentiation to plasma cells. In this review, recent advances in the genetic and epigenetic regulators of tumor progression are discussed. Risk factors include IgM-monoclonal gammopathy of undermined significance, familial disease, and immunological factors. The clinical manifestations of the disease include those related to clonal infiltration of the BM, lymph nodes, and, rarely, other sites such as pulmonary or CNS infiltration (Bing-Neel syndrome). Other manifestations are related to the IgM monoclonal protein, including hyperviscosity, cryoglobulinemia, protein-protein interactions, Ab-mediated disorders such as neuropathy, hemolytic anemia, and Schnitzler syndrome. IgM deposition in organs can lead to amyloidogenic manifestations in WM. The diagnostic workup for a patient with WM and rare presentations of WM are described herein. Prognosis of WM depends on 5 major factors in the International Staging System, including age, anemia, thrombocytopenia, beta-2 microglobulin, and IgM level. The differential diagnosis of WM includes IgM-multiple myeloma, marginal zone lymphoma, mantle cell lymphoma, and follicular lymphoma.
引用
收藏
页码:586 / 594
页数:9
相关论文
共 58 条
[1]   Identification of Copy Number Abnormalities and Inactivating Mutations in Two Negative Regulators of Nuclear Factor-κB Signaling Pathways in Waldenstrom's Macroglobulinemia [J].
Braggio, Esteban ;
Keats, Jonathan J. ;
Leleu, Xavier ;
Van Wier, Scott ;
Jimenez-Zepeda, Victor H. ;
Valdez, Riccardo ;
Schop, Roelandt F. J. ;
Price-Troska, Tammy ;
Henderson, Kimberly ;
Sacco, Antonio ;
Azab, Feda ;
Greipp, Philip ;
Gertz, Morie ;
Hayman, Suzanne ;
Rajkumar, S. Vincent ;
Carpten, John ;
Chesi, Marta ;
Barrett, Michael ;
Stewart, A. Keith ;
Dogan, Ahmet ;
Bergsagel, Leif ;
Ghobrial, Irene M. ;
Fonseca, Rafael .
CANCER RESEARCH, 2009, 69 (08) :3579-3588
[2]   Immune mediated neuropathies - An update on therapeutic strategies [J].
Czaplinski, A ;
Steck, AJ .
JOURNAL OF NEUROLOGY, 2004, 251 (02) :127-137
[3]   Schnitzler syndrome: Beyond the case reports: Review and follow-up of 94 patients with an emphasis on prognosis and treatment [J].
de Koning, Heleen D. ;
Bodar, Evelien J. ;
van der Meer, Jos W. M. ;
Simon, Anna .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2007, 37 (03) :137-148
[4]   Prognostic factors and response to fludarabine therapy in patients with Waldenstrom macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003) [J].
Dhodapkar, MV ;
Jacobson, JL ;
Gertz, MA ;
Rivkin, SE ;
Roodman, GD ;
Tuscano, JM ;
Shurafa, M ;
Kyle, RA ;
Crowley, JJ ;
Barlogie, B .
BLOOD, 2001, 98 (01) :41-48
[5]   Waldenstrom's macroglobulinemia: Clinical features, complications, and management [J].
Dimopoulos, MA ;
Panayiotidis, P ;
Moulopoulos, LA ;
Sfikakis, P ;
Dalakas, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :214-226
[6]   Diagnosis and management of Waldenstrom's macroglobulinemia [J].
Dimopoulos, MA ;
Kyle, RA ;
Anagnostopoulos, A ;
Treon, SP .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (07) :1564-1577
[7]   The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia [J].
Dimopoulos, MA ;
Gika, D ;
Zervas, K ;
Kyrtsonis, MC ;
Symeonidis, A ;
Anagnostopoulos, A ;
Bourantas, K ;
Matsouka, C ;
Pangalis, GA .
LEUKEMIA & LYMPHOMA, 2004, 45 (09) :1809-1813
[8]   Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia [J].
Dimopoulos, MA ;
Hamilos, G ;
Zervas, K ;
Symeonidis, A ;
Kouvatseas, G ;
Roussou, P ;
Gika, D ;
Karmiris, T ;
Bourantas, K ;
Zomas, A ;
Mitsouli, C ;
Xilouri, I ;
Vervessou, E ;
Matsis, K ;
Anagnostopoulos, N ;
Economopoulos, T .
ANNALS OF ONCOLOGY, 2003, 14 (08) :1299-1305
[9]   Update on Treatment Recommendations From the Fourth International Workshop on Waldenstrom's Macroglobulinemia [J].
Dimopoulos, Meletios Athanasios ;
Gertz, Morie A. ;
Kastritis, Efstathios ;
Garcia-Sanz, Ramon ;
Kimby, Eva K. ;
LeBlond, Veronique ;
Fermand, Jean-Paul ;
Merlini, Giampaolo ;
Morel, Pierre ;
Morra, Enrica ;
Ocio, Enrique M. ;
Owen, Roger ;
Ghobrial, Irene M. ;
Seymour, John ;
Kyle, Robert A. ;
Treon, Steven P. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (01) :120-126
[10]   Scintigraphic pattern of skeletal involvement of Waldenstrom macroglobulinemia [J].
Elmonayeri, Magda S. ;
Elgazzar, Abdelhamid H. .
CLINICAL NUCLEAR MEDICINE, 2008, 33 (08) :585-586